Shanghai RAAS Blood Products Co Ltd Class A (SHE:002252) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai RAAS Blood Products Co Ltd Class A (002252)
Shanghai RAAS Blood Products Co Ltd Class A (SHE:002252) has a market capitalization of $4.87 Billion (CN¥33.26 Billion) as of June 15, 2026. Listed on the SHE stock exchange, this China-based company holds position #3651 globally and #530 in its home market, demonstrating a -2.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai RAAS Blood Products Co Ltd Class A's stock price CN¥5.01 by its total outstanding shares 6637984837 (6.64 Billion). Review Shanghai RAAS Blood Products Co Ltd Clas total liabilities to assess the company's total debt and financial obligations.
Shanghai RAAS Blood Products Co Ltd Class A Market Cap History: 2015 to 2026
Shanghai RAAS Blood Products Co Ltd Class A's market capitalization history from 2015 to 2026. Data shows change from $20.91 Billion to $4.87 Billion (-13.28% CAGR).
Shanghai RAAS Blood Products Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.84x
Shanghai RAAS Blood Products Co Ltd Class A's market cap is 0.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.91x
Shanghai RAAS Blood Products Co Ltd Class A's market cap is 3.91 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $21.88 Billion | $2.33 Billion | $1.61 Billion | 9.40x | 13.56x |
| 2017 | $18.84 Billion | $1.93 Billion | $835.83 Million | 9.77x | 22.54x |
| 2018 | $7.61 Billion | $1.80 Billion | -$1.52 Billion | 4.22x | N/A |
| 2019 | $7.05 Billion | $2.58 Billion | $607.89 Million | 2.73x | 11.59x |
| 2020 | $7.03 Billion | $2.76 Billion | $1.32 Billion | 2.55x | 5.31x |
| 2021 | $6.50 Billion | $4.29 Billion | $1.29 Billion | 1.52x | 5.02x |
| 2022 | $6.08 Billion | $6.57 Billion | $1.88 Billion | 0.93x | 3.23x |
| 2023 | $7.70 Billion | $7.96 Billion | $1.78 Billion | 0.97x | 4.33x |
| 2024 | $7.01 Billion | $8.18 Billion | $2.19 Billion | 0.86x | 3.20x |
| 2025 | $6.16 Billion | $7.35 Billion | $1.58 Billion | 0.84x | 3.91x |
Competitor Companies of 002252 by Market Capitalization
Companies near Shanghai RAAS Blood Products Co Ltd Class A in the global market cap rankings as of June 15, 2026.
Key companies related to Shanghai RAAS Blood Products Co Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
Shanghai RAAS Blood Products Co Ltd Class A Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai RAAS Blood Products Co Ltd Class A's market cap moved from $20.91 Billion to $ 4.87 Billion, with a yearly change of -13.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.87 Billion | -20.98% |
| 2025 | CN¥6.16 Billion | -12.19% |
| 2024 | CN¥7.01 Billion | -8.91% |
| 2023 | CN¥7.70 Billion | +26.72% |
| 2022 | CN¥6.08 Billion | -6.60% |
| 2021 | CN¥6.50 Billion | -7.53% |
| 2020 | CN¥7.03 Billion | -0.18% |
| 2019 | CN¥7.05 Billion | -7.37% |
| 2018 | CN¥7.61 Billion | -59.61% |
| 2017 | CN¥18.84 Billion | -13.90% |
| 2016 | CN¥21.88 Billion | +4.65% |
| 2015 | CN¥20.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Shanghai RAAS Blood Products Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.87 Billion USD |
| MoneyControl | $4.87 Billion USD |
| MarketWatch | $4.87 Billion USD |
| marketcap.company | $4.87 Billion USD |
| Reuters | $4.87 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more